Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037192 | 1.00 | ACACB (0.50) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL13660693 | 1.00 | ACACB (0.50) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL28613611 | 0.88 | ITGB3 (0.50) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL14640271 | 0.87 | FPR2 (0.60) | ACACBPPARGFPR2LDHAACE | |
| SCHEMBL8751953 | 0.85 | ACACB (0.48) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL29398348 | 0.85 | ACACB (0.61) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL29401256 | 0.85 | ACACB (0.61) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL8751950 | 0.85 | ACACB (0.48) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL27569374 | 0.84 | ITGB3 (0.56) | ACACBITGB3ITGA2BPPARGABCB1 | |
| SCHEMBL27569376 | 0.84 | ITGB3 (0.56) | ACACBITGB3ITGA2BPPARGABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025047793-A1 | NOVEL COMPOUND HAVING ACTIVITY-ENHANCING EFFECT ON ANTIFUNGAL DRUGS, AND METHOD FOR PRODUCING SAME | 学校法人北里研究所 | 2025-03-06 | — | — | WO | disclosed |
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-10633630-B2 | Acceleration of Mycobacterium growth | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3158053-B1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-2061886-B1 | Small cationic immunomodulatory peptides | UNIV BRITISH COLUMBIA (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ACACB 762/4885ITGB3 4540/4885ITGA2B 4399/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ACACB 762/4885ITGB3 4540/4885ITGA2B 4399/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ACACB 762/4885ITGB3 4540/4885ITGA2B 4399/4885 |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ACACB 1035/4885ITGB3 4755/4885ITGA2B 4671/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ACACB 762/4885ITGB3 4540/4885ITGA2B 4399/4885 |
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | ACACB 3864/4885ITGB3 3772/4885ITGA2B 4363/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | ACACB 3864/4885ITGB3 3772/4885ITGA2B 4363/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ACACB 1035/4885ITGB3 4755/4885ITGA2B 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.